there is little evidence to suggest the NOACs are superior to warfarin in the prevention of secondary stroke in patients with AF. A recent meta-analysis of the RE-LY, ROCKET-AF and ARISTOTLE trials demonstrated that dabigatran, rivaroxaban and apixaban were all noninferior to warfarin in this respect